Suppression of Pentylenetetrazol
It has been well established that carnitine is an essential cofactor for the transport of long-chain acyl CoA through the inner mitochondrial membrane'. A recent study revealed primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter (OCTN2)".
Based on the examination of nearly 1,000 workers, who had a lower level of free carnitine in serum than those with wild types of OCTN2, the prevalence of heterozygotes of OCTN2 was estimated to be more than I%", suggesting that workers predisposed to carnitine deficiency are not very rare. Furthermore, chemicals, especially lipophilic organic cations, can potently inhibit OCTN2-mediated carnitine transport". Carnitine deficiency may also be secondarily caused a large number of conditions". In view of these findings and the fact that carnitine has the potential to conjugate various xenobiotics", carnitine appears important in occupational health.
In the present study, to evaluate the beneficial effects of L-carnitine in chemically induced seizures, seizure development after PTZ with L or D-carnitine pretreatment was analyzed in detail. In addition, the c fos gene in the brain, the expression of which has been reported to increase after PTZ treatment"", was examined by reverse transcription-polymerase chain reaction (RT-PCR) analysis.
Materials and Methods
PTZ, L-carnitine (inner salt) and D-carnitine (inner salt) were obtained from Sigma Chemical Co. (St. Louis, MO, USA), and dissolved in 0.85% NaCI. Male ddY mice weighing 28-33 g were administered with chemicals intraperitoneally. PTZ (50 mg/kg) was injected 30 min after the administration of saline, L carnitine (10 mmol/kg) or D-carnitine (10 mmol/kg). In the controls, saline was injected 30 min after the first administration of saline.
The behavior of the mice was recorded with a Sony CCD-TR850 video recorder for 20 min after PTZ injection and subsequently analyzed. The seizures were classified according to Erdtmann-Vourliotis et al." I as follows: stage 0, no response; stage 1, ear and facial twitching; stage 2, myoclonic jerks without upright position; stage 3, myoclonic jerks, upright position with bilateral forelimb clonus; stage 4, clonic-tonic seizures; stage 5, generalized clonic-tonic seizures, loss of postural control. The time to the first occurrence of clonic seizure was also determined.
Twenty min after the injection of PTZ or the second saline, the mice were killed by decapitation and immersed quickly in liquid nitrogen. The frozen brain was dissected out and homogenized with a Polytron PT 3000. The isolation of total RNA and RT-PCR analysis were carried out as described previously").
The c-fos and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) primers were obtained from Clontech (Palo Alto, CA, USA). After electrophoresis on an agarose gel containing ethidium bromide, the densitiy of each band was quantified. For mRNA analyses, the density of c fos product was normalized to that of GAPDH. Statistical analyses of seizure activities (seizure stage, overall seizure stage scores, and latency to the first clonic tonic seizure) and the c fos mRNA level in different treatment groups were done by the Kruskal-Wallis test followed by Dunn's test and by one-way analysis of variance (ANOVA) followed by Bonferroni's test, respectively. Differences at p<0.05 were considered statistically significant.
Results
In mice given saline plus PTZ, the mean value for the seizure stage peaked 2 min after PTZ injection, and thereafter lowered gradually (Fig. 1 A) . On the other hand, the pretreatment with L-carnitine delayed the peak to 4 min, and also lowered the seizure stage scores significantly at 2, 6 and 7 min when compared to the saline plus PTZ group (Fig. 1B) . In contrast, the pretreatment with D-carnitine did not affect the seizure scores significantly at any time (Fig. 1C) .
Overall seizure stage scores during the observation period (20 min) (Fig. 2 ) differed (p<0.01) for mice pretreated with saline and L-carnitine but not for those treated with saline and D-carnitine. When the scores in each group are expressed as the mean ± S.E.M., they are 31.43 ± 2.49, 10.57 ± 2.86 and 24.71 ± 3.05 (n=7) in saline, L-carnitine and D-carnitine groups, respectively.
The latency to the first clonic-tonic seizure (Fig. 3) also differed (p<0.05) for the saline and L-carnitine groups but not for the saline and D-carnitine groups.
In the semi-quantitative RT-PCR analysis, PTZ had increased the c fos mRNA level in the brain (p<0.05) when examined 20 min after its administration (Fig. 4) . The PTZ-induced increase in the c fos mRNA level was noticeably suppressed by the pretreatment with L-carnitine but not with D-carnitine (Fig. 4) .
Discussion
In our previous study3), in order to compare with the beneficial effects of carnitine in hyperammonemia13), we observed animal behavior for 10 min after PTZ, with 70 mg/kg PTZ and mainly with 20 mmol/kg carnitine. In the present experiment, we employed a smaller dose of PTZ (50 mg/kg) and analyzed seizures over 20 min in detail recorded on a videotape. As a result, we found that the pretreatment with L-carnitine clearly suppressed the PTZ-induced seizures even at 10 mmol/kg. On the other hand, the same dose of D-carnitine, a physiologically inactive form of carnitine, failed to suppress seizures. The anticonvulsive effects of L-carnitine therefore seem due to the inherent action of L-carnitine rather than non specific actions. L-Carnitine is widely distributed among tissues including the brain". It can be synthesized in the brain"'. When administered peripherally, carnitine can be taken up by the brain irrespective of the route of administration"', but the physiological function of carnitine in the brain is not known. Not only myopathy but hyperammonemia and hypoketotic hypoglycemic encephalopathy may be seen in primary systemic carnitine deficieny'y'. In this regard, it is of interest that carnitine treatment in mice intoxicated with ammonia suppressed seizures, ameliorated energy metabolism of the brain and moreover lowered the ammonia level in the brain'"'.
As shown in the present experiments, L-carnitine can suppress PTZ-induced seizures clinically and it also suppresses a gene expression in the brain caused by PTZ, though the mechanism of these beneficial effects of carnitine is still not clear. Activity in the PTZ model often indicates that a drug can affect GABAergic systems, either by enhancing brain GABA levels or by altering the sensitivity of postsynaptic GABA receptors2'. It was reported that GABA competitively inhibits carnitine transport in rat brain slices"', suggesting that the same system mediates the transport for GABA and carnitine in the brain. On the other hand, carnitine and GABA did not compete in the OCTN2-mediated transport expressed in HEK293 cells21'. In addition, the brain has low expression of OCTN221 . These findings suggest that the anticonvulsive effects of carnitine seen in the present experiments might not involve the transport of carnitine through OCTN2 in the brain.
Previous experiments indicate that L-carnitine may protect the brain from ischemia2 2223 1 and hyperammonemia'" 24' in animals. Patients with Alzheimer's disease treated for one year with acetyl-L carnitine had a slowed rate of deterioration in neuropsychological tests and in the performance of every day activities25'. They also suggest that L-carnitine and its analogues may have the potential to protect the cerebral functions in humans as well as in animals. To understand its mechanism, it remains to be determined whether the levels of carnitine in the brain and other tissues are affected by chemicals especially by convulsants including PTZ. 
